Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost symptoms of taking Wegovy are gastrointestinal and appear early in treatment, most commonly nausea, loose stools or constipation, and a significant drop in appetite. They tend to be at their worst after your first injection or after a dose increase, and for most people they ease within one to two weeks. Wegovy (semaglutide) is a prescription-only medicine, which means a prescriber assesses whether it is appropriate for you before treatment starts — the symptoms you experience, and how they're managed, are part of that ongoing clinical conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Here is the misconception that causes the most unnecessary anxiety: if you feel nauseous in your first week on Wegovy, it does not mean the medicine is harming you or that treatment has failed. Nausea is, in fact, a sign that semaglutide is doing exactly what it is designed to do, slowing the rate at which food leaves your stomach and acting on appetite-regulating receptors in the brain. Discomfort is common; it is rarely a reason to stop.
The NHS medicines page for semaglutide lists nausea as the most frequently reported symptom, followed by vomiting, diarrhoea, constipation, stomach pain, reflux and burping. Fatigue, headache and dizziness also appear, particularly around the time of a dose step-up. Injection-site reactions (mild redness or a small lump at the site) are possible too, and rotating between your abdomen, thigh and upper arm helps reduce them.
What most people find is that the first three to five days after each new dose are the roughest, and then things settle. By week three or four at a given dose, most of the GI symptoms have quietened considerably. That pattern repeats with each increase but usually becomes less pronounced as treatment continues. Understanding this rhythm makes it far easier to stay the course when the first week feels uncomfortable. For a closer look at how the body responds in the early days, our page on semaglutide symptoms from day one goes through the early-adjustment period in detail.
Breaking symptoms into groups makes them easier to anticipate. The gastrointestinal group is by far the largest: nausea, vomiting, diarrhoea and constipation can each occur in isolation or together, and they tend to be mild to moderate rather than severe. Eating smaller portions, choosing lower-fat foods and avoiding alcohol all help keep them manageable. Sipping water steadily through the day matters too, if vomiting or diarrhoea is significant, the risk of dehydration is real and can, in turn, affect kidney function.
Headache and fatigue are in a second category and are often under-discussed. They are less obviously linked to semaglutide in people's minds, but they do appear in trial data and are more common around dose increases. Dizziness occasionally follows, sometimes connected to reduced calorie intake or dehydration rather than the medicine itself.
Injection-site symptoms form their own small category: transient redness, warmth or itching at the injection point. Proper technique and rotating sites consistently keeps these minimal. If you want to understand what the full symptom profile looks like compared with other reported effects, the detailed breakdown of Wegovy symptoms covers each one with context. People sometimes also ask whether Wegovy can cause urinary symptoms; that question is addressed specifically on our page about Wegovy and UTI symptoms.
Hair thinning is reported anecdotally by some people losing weight quickly on any treatment, including Wegovy. This is generally attributed to the physiological stress of rapid weight change rather than a direct drug effect, and it is usually temporary. It is worth mentioning to your prescriber if it concerns you.
Most symptoms of taking Wegovy are self-limiting and manageable. A smaller number are signals that need medical attention promptly, and it is important to know them before you start treatment rather than trying to look them up when you feel unwell.
Severe, persistent pain in your stomach or abdomen that radiates to the back, with or without vomiting, is the key warning sign for acute pancreatitis. This is uncommon, but in January 2026 the MHRA issued a Drug Safety Update on GLP-1 medicines specifically highlighting pancreatitis as a known risk, infrequent but potentially serious. If that symptom pattern fits, stop taking Wegovy and get medical help the same day.
Gallbladder problems are also more common during significant weight loss: right-sided upper abdominal pain, especially after eating fatty food, is the classic pattern. Signs of a serious allergic reaction (swelling of the face, throat or lips, difficulty breathing, rapid heartbeat) need emergency care. Severe dehydration from persistent vomiting or diarrhoea should be treated promptly. Low mood or thoughts of self-harm are listed in prescribing information and should be reported to a healthcare professional straight away.
If you have ever stopped Wegovy and experienced a distinct change in how you felt, our page on symptoms of stopping Wegovy covers what the evidence says about that transition. Side effects can also be reported directly to the MHRA via the Yellow Card scheme, it takes only a few minutes and contributes to ongoing medicine safety monitoring.
The practical side of symptom management is something our prescribers are asked about most weeks: when should you eat, how much, does timing the injection matter? A few things are reliably useful. Eating before your injection day, keeping portions smaller than usual in the days that follow, staying well hydrated and moving gently rather than lying down after eating all reduce nausea meaningfully for most people.
You will find a fair amount of general information about Wegovy on our Wegovy treatment page, including how the dose schedule works and what the broader clinical picture looks like. It is also worth reading the full semaglutide overview on our semaglutide information page if you are weighing up options. Thinking about cost alongside treatment? The weight-loss treatments overview sets out what private treatment involves and what to expect from the process.
One practical note on timing: if you order by 12pm on a weekday and your consultation is approved, dispatch happens the same day. That means your pen (stored in the fridge door when it arrives) lands with you the next working day via DPD. The symptom experience in week one is personal, but having good clinical support behind you makes it considerably easier to navigate. When treatment finishes, or if you decide to pause, your prescriber reviews that too. Every repeat at nume goes back to a clinician before anything is sent.
If you have questions, our team is reachable seven days a week via the contact page. And if you are ready to find out whether Wegovy is clinically suitable for you, start your free consultation, a GPhC-registered prescriber, not software, reads your answers and responds the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.